These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32776377)

  • 41. Accounting for "lost pleasure" in a cost-benefit analysis of government regulation: the case of the Food and Drug Administration's proposed cigarette labeling regulation.
    Chaloupka FJ; Gruber J; Warner KE
    Ann Intern Med; 2015 Jan; 162(1):64-5. PubMed ID: 25322210
    [No Abstract]   [Full Text] [Related]  

  • 42. Animal farm--the ethics and public policy of xenotransplantation.
    duRivage J
    Princet J Bioeth; 2000; 3(1):8-19. PubMed ID: 11933983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA withholds xeno data.
    Fox JL
    Nat Biotechnol; 2001 Jan; 19(1):6. PubMed ID: 11135517
    [No Abstract]   [Full Text] [Related]  

  • 44. Xenotransplantation at a crossroads: prevention versus progress.
    Allan JS
    Nat Med; 1996 Jan; 2(1):18-21. PubMed ID: 8564824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of Clinical Xenotransplantation: A Reappraisal of the Legal, Ethical, and Social Aspects Involved.
    Jorqui-Azofra M
    Methods Mol Biol; 2020; 2110():315-358. PubMed ID: 32002917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ethics of xenotransplantation: animal issues, consent, and likely transformation of transplant ethics.
    Daar AS
    World J Surg; 1997; 21(9):975-82. PubMed ID: 9361514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. British, American reports on xenotransplantation.
    Marwick C
    JAMA; 1996 Aug; 276(8):589-90. PubMed ID: 8773620
    [No Abstract]   [Full Text] [Related]  

  • 49. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advancing regulatory science to bring novel medical devices for use in emergency care to market: the role of the Food and Drug Administration.
    Scully CG; Forrest S; Galeotti L; Schwartz SB; Strauss DG
    Ann Emerg Med; 2015 Apr; 65(4):400-3. PubMed ID: 25128009
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA subcommittee finds no evidence of PERV transmission.
    Birmingham K
    Nat Med; 1999 Aug; 5(8):855. PubMed ID: 10426294
    [No Abstract]   [Full Text] [Related]  

  • 52. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Xenotransplantation under FDA spotlight.
    Brower V
    Nat Med; 1998 Feb; 4(2):135-6. PubMed ID: 9461168
    [No Abstract]   [Full Text] [Related]  

  • 54. Off-label use of medical devices in radiology: regulatory standards and recent developments.
    Smith JJ
    J Am Coll Radiol; 2010; 7(2):115-9. PubMed ID: 20142085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Success from failure: US federal commercial tobacco regulation.
    Jenson D
    Tob Control; 2022 Mar; 31(2):212-215. PubMed ID: 35241590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Public health concerns take center stage in Nuffield Council on Bioethics: a review of Animal-to-Human Transplants: The Ethics of Xenotransplantation.
    Allan JS
    Sci Eng Ethics; 1996 Oct; 2(4):486-90. PubMed ID: 11657736
    [No Abstract]   [Full Text] [Related]  

  • 57. Addressing health disparities in the Food and Drug Administration's artificial intelligence and machine learning regulatory framework.
    Ferryman K
    J Am Med Inform Assoc; 2020 Dec; 27(12):2016-2019. PubMed ID: 32951036
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulatory pathways to the market: an overview.
    Morton WA
    Artif Organs; 1982 Nov; 6(4):463-9. PubMed ID: 6762190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal xenotransplantation: experimental progress and clinical prospects.
    Wijkstrom M; Iwase H; Paris W; Hara H; Ezzelarab M; Cooper DK
    Kidney Int; 2017 Apr; 91(4):790-796. PubMed ID: 27914702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The road to market implantable drug delivery systems: a review on US FDA's regulatory framework and quality control requirements.
    Al-Jawadi S; Capasso P; Sharma M
    Pharm Dev Technol; 2018 Dec; 23(10):953-963. PubMed ID: 30084277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.